Which pharmaceutical companies are currently developing treatments for prostate cancer?

Several pharmaceutical companies are actively developing treatments for prostate cancer. Some of the key players include: 1. **Actinium Pharmaceuticals, Inc.**: The company is developing ATNM-400, a radiotherapy candidate that has shown efficacy against treatment-resistant prostate cancer. It targets prostate cancer cells by delivering the alpha-emitter radioisotope Actinium-225. 2. **AstraZeneca**: AstraZeneca is conducting a Phase I clinical trial titled A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. The study is assessing the safety and tolerability of AZD2284, AZD2287, and AZD2275. 3. **Johnson & Johnson**: The company is developing pasritamig, a first-in-class bispecific T-cell-engaging antibody for metastatic castration-resistant prostate cancer (mCRPC). It targets KLK2, a prostate cancer-specific biomarker. 4. **Hengrui Medicine**: The company has obtained approval for a prostate cancer trial and is likely developing new treatments in this space. 5. **Parexel International**: They are collaborating with AstraZeneca on the Phase I clinical trial of AZD2284, AZD2287, and AZD2275, assessing their safety and efficacy in treating metastatic castration-resistant prostate cancer. These companies are at various stages of development, from preclinical trials to Phase I clinical trials, indicating ongoing innovation in prostate cancer treatment.